Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-108,572
| Closed | -$13.6M | – | 194 |
|
|
2025
Q2 | $13.6M | Sell |
108,572
-45,397
| -29% | -$5.66M | 0.04% | 352 |
|
|
2025
Q1 | $21.1M | Sell |
153,969
-7,667
| -5% | -$1.1M | 0.07% | 265 |
|
|
2024
Q4 | $24.7M | Buy |
161,636
+103,677
| +179% | +$17.5M | 0.08% | 238 |
|
|
2024
Q3 | $11.2M | Sell |
57,959
-14,043
| -20% | -$2.94M | 0.03% | 374 |
|
|
2024
Q2 | $16.7M | Sell |
72,002
-335,836
| -82% | -$73M | 0.05% | 296 |
|
|
2024
Q1 | $87.9M | Sell |
407,838
-42,905
| -10% | -$10M | 0.26% | 84 |
|
|
2023
Q4 | $117M | Buy |
450,743
+9,494
| +2% | +$2.33M | 0.38% | 60 |
|
|
2023
Q3 | $113M | Buy |
441,249
+1,047
| +0.2% | +$280K | 0.4% | 55 |
|
|
2023
Q2 | $125M | Buy |
440,202
+24,198
| +6% | +$7.2M | 0.42% | 52 |
|
|
2023
Q1 | $116M | Buy |
416,004
+29,308
| +8% | +$8.11M | 0.4% | 56 |
|
|
2022
Q4 | $107M | Buy |
386,696
+136,991
| +55% | +$38.7M | 0.39% | 53 |
|
|
2022
Q3 | $66.7M | Buy |
249,705
+36,058
| +17% | +$7.66M | 0.26% | 95 |
|
|
2022
Q2 | $43.6M | Buy |
213,647
+10,292
| +5% | +$2.1M | 0.16% | 150 |
|
|
2022
Q1 | $42.8M | Sell |
203,355
-18,198
| -8% | -$3.96M | 0.12% | 189 |
|
|
2021
Q4 | $53.2M | Buy |
221,553
+11,866
| +6% | +$3.05M | 0.14% | 182 |
|
|
2021
Q3 | $59.3M | Buy |
209,687
+15,754
| +8% | +$5.16M | 0.17% | 158 |
|
|
2021
Q2 | $67.2M | Buy |
193,933
+24,043
| +14% | +$7.28M | 0.19% | 128 |
|
|
2021
Q1 | $47.5M | Buy |
169,890
+23,137
| +16% | +$6.24M | 0.14% | 176 |
|
|
2020
Q4 | $35.9M | Sell |
146,753
-39,814
| -21% | -$10.3M | 0.11% | 207 |
|
|
2020
Q3 | $52.9M | Sell |
186,567
-67,621
| -27% | -$18.9M | 0.19% | 127 |
|
|
2020
Q2 | $68M | Buy |
254,188
+68,828
| +37% | +$20.7M | 0.27% | 93 |
|
|
2020
Q1 | $58.6M | Buy |
185,360
+5
| +0% | +$1.52K | 0.29% | 82 |
|
|
2019
Q4 | $55M | Buy |
185,355
+21,326
| +13% | +$5.92M | 0.22% | 109 |
|
|
2019
Q3 | $38.2M | Sell |
164,029
-30,483
| -16% | -$7.1M | 0.15% | 179 |
|
|
2019
Q2 | $45.5M | Sell |
194,512
-26,592
| -12% | -$6.14M | 0.18% | 160 |
|
|
2019
Q1 | $52.3M | Sell |
221,104
-129,765
| -37% | -$40.9M | 0.2% | 137 |
|
|
2018
Q4 | $106M | Sell |
350,869
-35,598
| -9% | -$11.4M | 0.46% | 41 |
|
|
2018
Q3 | $137M | Buy |
386,467
+1,873
| +0.5% | +$645K | 0.5% | 39 |
|
|
2018
Q2 | $112M | Buy |
384,594
+1,099
| +0.3% | +$309K | 0.43% | 51 |
|
|
2018
Q1 | $105M | Buy |
383,495
+2,289
| +0.6% | +$711K | 0.42% | 57 |
|
|
2017
Q4 | $121M | Sell |
381,206
-40,016
| -9% | -$12.8M | 0.48% | 38 |
|
|
2017
Q3 | $132M | Sell |
421,222
-48,439
| -10% | -$14.3M | 0.57% | 32 |
|
|
2017
Q2 | $127M | Buy |
469,661
+8,378
| +2% | +$2.22M | 0.58% | 28 |
|
|
2017
Q1 | $126M | Buy |
461,283
+15,241
| +3% | +$4.31M | 0.57% | 27 |
|
|
2016
Q4 | $126M | Sell |
446,042
-36,712
| -8% | -$10.9M | 0.59% | 27 |
|
|
2016
Q3 | $151M | Sell |
482,754
-20,716
| -4% | -$6.14M | 0.66% | 23 |
|
|
2016
Q2 | $122M | Sell |
503,470
-28,836
| -5% | -$7.6M | 0.54% | 33 |
|
|
2016
Q1 | $139M | Sell |
532,306
-56,610
| -10% | -$15M | 0.62% | 31 |
|
|
2015
Q4 | $180M | Buy |
588,916
+69,067
| +13% | +$19.8M | 0.79% | 18 |
|
|
2015
Q3 | $152M | Buy |
519,849
+71,333
| +16% | +$23.6M | 0.62% | 27 |
|
|
2015
Q2 | $181M | Buy |
448,516
+30,539
| +7% | +$12.3M | 0.73% | 19 |
|
|
2015
Q1 | $176M | Buy |
417,977
+43,974
| +12% | +$17.3M | 0.73% | 18 |
|
|
2014
Q4 | $127M | Buy |
374,003
+68,811
| +23% | +$22.3M | 0.51% | 46 |
|
|
2014
Q3 | $101M | Buy |
305,192
+68,106
| +29% | +$22.5M | 0.43% | 49 |
|
|
2014
Q2 | $74.8M | Sell |
237,086
-38,686
| -14% | -$11.6M | 0.31% | 81 |
|
|
2014
Q1 | $84.3M | Buy |
275,772
+21,336
| +8% | +$6.77M | 0.37% | 60 |
|
|
2013
Q4 | $71.2M | Buy |
254,436
+58,622
| +30% | +$15.2M | 0.32% | 79 |
|
|
2013
Q3 | $47.1M | Buy |
195,814
+45,851
| +31% | +$10.3M | 0.23% | 117 |
|
|
2013
Q2 | $32.3M | Buy |
+149,963
| New | +$32M | 0.17% | 157 |
|
Other funds holding BIIB
Axa's BIIB Position: Q3 2025 in Review
Axa sold out of Biogen (BIIB) in Q3 2025, closing a stake of 108,572 shares — an estimated $13.6M sold.
Axa first reported a position in BIIB in Q2 2013 and held it in 49 quarters. The position peaked at $181M in Q2 2015. 906 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.
- Axa reported no remaining Biogen position as of Q3 2025 after selling out during the quarter.
- Axa sold 108,572 Biogen shares in Q3 2025, an estimated $13.6M.
- Axa first reported a position in Biogen in Q2 2013 and held it in 49 quarters.
- Axa's Biogen position peaked at $181M in Q2 2015.
- 906 funds tracked by Wall St. Rank held Biogen as of Q3 2025.
Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.